Business UpdateMay 26, 2026, 08:02 AM
LENZ Therapeutics to Attend Three Investor Conferences in June
AI Summary
LENZ Therapeutics, Inc. announced that its management will participate in three upcoming investor conferences in June 2026. The company plans to hold 1x1 investor meetings at the William Blair 46th Annual Growth Stock Conference, the 2026 Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia.
Key Highlights
- LENZ Therapeutics management will participate in the William Blair 46th Annual Growth Stock Conference on June 2, 2026.
- The company will attend the 2026 Jefferies Global Healthcare Conference on June 3, 2026.
- LENZ management is scheduled to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026.
- All three investor conferences will feature 1x1 investor meetings.
- LENZ Therapeutics focuses on commercializing VIZZ , an FDA-approved eye drop for presbyopia.
- VIZZ treats presbyopia, a condition affecting an estimated 1.8 billion people globally.
Price Impact
More from LENZ